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Abstract: Pyrrolomycins (PMs) are polyhalogenated antibiotics known as powerful biologically 
active compounds, yet featuring high cytotoxicity. The present study reports the antibacterial and 
antitumoral properties of new chemically synthesized PMs, where the three positions of the pyrrolic 
nucleus were replaced by nitro groups, aiming to reduce their cytotoxicity while maintaining or 
even enhancing the biological activity. Indeed, the presence of the nitro substituent in diverse 
positions of the pyrrole determined an improvement of the minimal bactericidal concentration 
(MBC) against Gram-positive (i.e., Staphylococcus aureus) or -negative (i.e., Pseudomonas aeruginosa) 
pathogen strains as compared to the natural PM-C. Moreover, some new nitro-PMs were as active 
as or more than PM-C in inhibiting the proliferation of colon (HCT116) and breast (MCF 7) cancer 
cell lines and were less toxic towards normal epithelial (hTERT RPE-1) cells. Altogether, our findings 
contribute to increase the knowledge of the mode of action of these promising molecules and 
provide a basis for their rationale chemical or biological manipulation. 
Keywords: heterocycles; pyrrolic nucleus; pyrrolomycin; antibacterial activity; Pseudomonas 
aeruginosa; Staphylococcus aureus; antitumoral activity; HCT116; MCF 7 
 
1. Introduction 
Pyrrolomycins (PMs) are a family of polyhalogenated antibiotics isolated from the fermentation 
broth of Actinosporangium and Streptomyces species [1]. The chemical structure of these metabolites 
consists of a pyrrole moiety linked to a hydroxyphenyl ring via a one-carbon bridge and characterized 
by the presence of electron-withdrawing groups (Figure 1). The most remarkable features of these 
compounds are the pyrrolic nucleus containing three modifiable positions and ionizable groups (i.e., 
the pyrrole NH and the phenolic OH). Representative examples of PMs include the natural one, 
named as C [2], and that of chemogenic synthesis, called PM 1 [3,4]. PM-C can be defined as a 
tetrachlorine compound since it features two chlorine atoms on both the pyrrolic and the phenolic 
moieties; differently, the synthetic PM 1 contains five bromines on its scaffold, and this represents 
the most active pyrrolomycin against Staphylococcus aureus synthesized so far [5]. 
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Figure 1. Chemical structure of some natural pyrrolomycins (PMs) and the synthetic one PM 1. 
Pyrrolomycins are recognized as molecules with diverse biological activities; indeed, they show 
potent antimicrobial and antibiofilm properties mainly against Gram-positive bacteria [5–11]. 
Besides, some of them display anthelmintic activity [12], as well as neuro-modulatory [13], immune-
modulatory [14], insecticidal [15] and anticancer properties. The latter was demonstrated either alone 
[10,11,16,17] or in combination with other molecules (i.e. the mTOR inhibitor temsirolimus) [18].  
However, as sound and promising as PMs properties can appear, their polyhalogenation degree 
could impair their application for biomedical purposes, since, for example, PM-C shows acute 
toxicity on mice [19].  
Through chemical manipulation, PMs with less toxic moieties could be achieved for improving, 
on one hand, PMs pharmacokinetic and decreasing their cytotoxicity on the other. Considering that 
the biological activity of PMs is strictly dependent on the halogens of the pyrrolic nucleus, their 
replacement with other less toxic electron-withdrawing moieties (i.e., nitro groups) can represent a 
valid strategy to obtain safer pyrrolomycins. 
This aspect can be addressed through synthetic procedures, such as the Microwave-Assisted 
Organic Synthesis (MAOS), which cost-effectively allows generating new PMs, introducing desired 
substituents in specific positions by a target manipulation of these compounds [9].  
The effect of specific chemical modifications on the biological activity can also be helpful to 
investigate the mode of action of a compound. PMs are thought to explicate their function by binding 
sortase A in the Gram-positive strain S. aureus [9,20,21]. Recently, PMs, such as PM-C and PM-D, 
were shown to be powerful depolarizing membrane agents capable of specifically disturbing the 
proton gradient and decoupling oxidative phosphorylation by protonophoric action [11]. Although 
PM-C resulted more effective than PM-D in depolarizing the membrane potential, the biological 
activity of PM-D on both bacterial and cancer cells was greater, likely for its increased lipophilicity 
and therefore ability to permeate the membrane [11].  
Here, taking advantage of previous investigations of some of us [4–9] that allowed to 
synthetically produce halogenated PMs with high yields by MAOS, new PMs were synthesized and 
their antibacterial and antitumoral activity was assayed. Firstly, the synthesis of the PM 2 (Scheme 1) 
from the hit compound 1 was carried out to evaluate the importance of the ionizable hydrogens and 
lipophilicity in the activity of the PMs, replacing, in the PM 2, the acid hydrogens of the pyrrole NH 
and phenolic OH groups with methyl ones.  
In addition, we introduced the nitro group on the pyrrolic nucleus, generating new nitro-PMs 
5a-d (Scheme 2). The nitro group in different positions led to generate PMs with diverse activity 
against Gram-positive (S. aureus) and -negative (Pseudomonas aeruginosa) pathogen strains compared 
to the PM-C and compound 1. Besides, the nitro-PMs displayed antitumoral activity towards colon 
(HCT116) and breast (MCF 7) cancer cell lines and, more importantly, featured lower toxicity levels 
towards normal epithelial (hTERT RPE-1) cells as compared to the natural PM-C. We also calculated 
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the ADMET (absorption, distribution, metabolism, excretion, and toxicity) profile of the new PMs 2 
and 5a–d to evaluate their pharmacokinetic and toxic properties. 
Our results suggested that the biological activity of PMs is due not only to the protonophoric 
action but also to the steric hindrance and narcotic effect derived from enhanced lipophilicity of PMs 
in the context of cellular membranes. Moreover, the biological activity of PMs can be modulated by 
the presence of more electron-withdrawing groups on the pyrrolic nucleus, as well as by the 
lipophilicity degree, overall representing factors of utmost importance that contribute to decreasing 
the PM cytotoxicity with respect to those naturally occurring. 
2. Results and Discussion 
2.1. Synthesis of new Pyrrolomycins 
The methyl-substituted PM 2 was synthesized starting from the pentabromo-pyrrolomycin 1, 
which was methylated using excesses of iodomethane (10 mmoles), anhydrous dimethylformamide 
(DMF) as a solvent, and anhydrous potassium carbonate to generate the salt. After 7 days of magnetic 
stirring, the organic solvent was removed under vacuum, being, afterward, the PM 2 purified by 
automated flash chromatography and crystallized (Scheme 1).  
 
Scheme 1. Experimental protocol to obtain compound 2. Reagents and reaction condition: (a) anhydrous 
dimethylformamide (DMF) as a solvent, anhydrous K2CO3, magnetic stirring, r.t., 30 min; CH3I (10 
mmoles excess), magnetic stirring, r.t., 7 days. 
The unsubstituted pyrrolomycin 3a was obtained with an experimental protocol as previously 
described [8]. The procedure to obtain pyrrolomycins 3b,d has already been set up through a MAOS 
approach, using N-bromosuccinimide (NBS) or N-chlorosuccinimide (NCS) as a source of halogens 
[9]. Since the presence of the acyl group influences the reactivity of the free positions (i.e., R1, R2, and 
R3) of the pyrrole itself, exploiting this aspect the nitro group was successfully and differently inserted 
on the pyrrolic nucleus. Furthermore, since the nitration reaction is not selective, to avoid the 
formation of complex reaction mixtures, it was performed at a low temperature and for a very short 
time. Consequently, the reaction was carried out using cold concentrated sulfuric acid as a solvent, 
an equimolar amount of sulfonitric mixture, and working at −10°C for 15 min under magnetic stirring. 
Then, the reaction was stopped through a fast work-up process, which involved the use of crushed 
ice to dilute and cool down the reaction mixture. Once the reaction intermediates were obtained, 
4a,b,d, these were quickly extracted by using diethyl ether as a solvent and, after evaporation, the 
crude compounds were purified by crystallization. As for the intermediate of reaction 4c, which 
precipitated as a solid in the reaction mixture, it was isolated by filtration and then crystallized. The 
O-demethylation reaction was performed using a large excess of aluminium chloride as Lewis acid 
(30 mmoles), in anhydrous dichloromethane as a solvent, cooling the reaction mixture with an ice-
salt bath. The reaction mixture was stirred overnight at room temperature, and then a cold 5% sulfuric 
acid solution was used to decompose the aluminium complex. The nitro-PMs 5a–d were obtained 
after extraction with diethyl ether and purified by crystallization (Scheme 2). 
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 3a 3b 3c 3d 4a 4b 4c 4d 5a 5b 5c 5d 
R1 H H H Cl H NO2 NO2 Cl H NO2 NO2 Cl 
R2 H Cl Br Cl NO2 Cl Br Cl NO2 Cl Br Cl 
R3 H H H H H H H NO2 H H H NO2 
Scheme 2. Experimental protocols to obtain compounds 4a–d and 5a–d. Reagents and reaction 
conditions: (a) cold concentrated sulfuric acid as a solvent, equimolar amount of sulfonitric mixture, T 
= −10 °C, magnetic stirring, 15 min; (b) anhydrous dichloromethane as a solvent, AlCl3 (30 mmoles 
excess), ice-salt bath; magnetic stirring, r.t., overnight; quenching with a cold 5% H2SO4 solution. 
Analytical and spectroscopic analyses were performed to establish the molecular structures of 
all new PMs (Figure S1). Specifically, 1H-NMR spectra of 4a-d showed (i) a singlet attributable to the 
methoxy group in the range of 3.71–3.73 δ, (ii) signals in the range of 7.02–8.27 δ for the aromatic 
protons, and (iii) a broad singlet, exchangeable with D2O, for the pyrrolic NH between 13.25 and 14.72 
δ. The presence of the pyrrolic NH was also confirmed by IR spectra that showed broadband in the 
range of 3174–3264 cm−1.  
Similar signals were present in the 1H-NMR spectra of PMs 5a-d for both aromatic protons and 
the pyrrolic NH; here, a broad singlet related to phenolic OH, exchangeable with D2O, in the range 
of 10.21-11.27 δ was detected instead of the methoxy group. The presence of the phenolic OH was 
also confirmed by IR spectra that showed broadband in the range of 3309–3585 cm−1. In the 1H-NMR 
spectra of the PM 2, two singlets related to NCH3 and OCH3 groups are present (3.73 and 3.92 δ, 
respectively), instead of the pyrrolic NH and phenolic OH. 13C-NMR and elemental analysis 
confirmed the structures. 
2.2. Antimicrobial Efficacy of New Pyrrolomycins 
Previous reports showed significant differences between the minimal inhibitory concentration 
(MIC) and the minimal bactericidal concentration (MBC) of pyrrolomycins [5,7,11]. Thus, in this 
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study, we compared the MBC of the new PMs to that of the natural PM-C—used as the starting 
compound for the synthesis of nitro-PMs—and to the synthetic PM 1, which was the precursor of the 
PM 2. The latter was included in the analysis to evaluate the influence of both ionizable hydrogens 
and hydrophobicity of PMs on biological activity. For the most performing PMs, we reported their 
MIC (Table S1).  
The kill curves of S. aureus ATCC 25923 and P. aeruginosa ATCC 10145 grown as planktonic cells 
demonstrated that nitro-PMs 5a–d and 2 displayed a diverse killing effect (Figure 2 and Table 1). 
Particularly, some PMs needed to reach a certain threshold concentration to explicate their 
bactericidal action. In this regard, a decrease (~3log) in the number of vital S. aureus cells occurred in 
the presence of increasing concentrations (up to 80 μM) of PM-C, while its highest concentration 
tested (90 μM) determined a bactericidal effect, as highlighted by the total killing of bacterial cells. 
Nevertheless, the bacteriostatic effect was even more enhanced when S. aureus cells were exposed to 
PM 2, 5a, 5b, and 5d, since a lesser amount of each PM was needed to roughly achieve the total kill 
of bacteria. For compound 5c and 1, this effect was less evident, likely due to their strongest 
bactericidal activity (Figure 2A). A reasonable explanation for the diverse mode of action (i.e., 
bacteriostatic versus bactericidal) elicited by PMs, depending on their concentration, might be 
ascribed to the lipophilic nature of these compounds. Indeed, hydrophobic compounds with a 
clogPo/w values higher than 2, and PMs do not represent an exception (Table 2), tend to partition 
better in the nonpolar context of the phospholipid bilayer, leading to the alteration of the cytoplasmic 
membrane fluidity and stability through a non-specific mode of action known as narcosis [22–24], 
which can result in severe disturbances of physiological functions, eventually leading to cell death 
[25–27]. To further sustain the importance of PMs’ lipophilicity, the antibacterial activity of the 
compound 1 was compared to its methoxy analogue (i.e., PM 2), whose MBC values were 5 μM and 
70 μM, respectively. In a previous report, it was shown that the O-methylated PM-I and PM-J were 
significantly less active than the non-methylated analogue [11], thus indicating that the ability of PMs 
to depolarize the membrane is not only attributable to the ionisable OH group present in the phenolic 
function, but also to that (i.e., NH) of the pyrrolic one. Here, although the (di)methylated PM 2 
displayed reduced antimicrobial activity, likely due to the lack of ionisable moieties, it was yet 
capable of completely inhibiting S. aureus growth at an effective concentration that was lower than 
PM-C (Figure 2A). This aspect on one hand emphasized the crucial role played by deprotonable 
groups in PMs, and on the other hand underlined the not negligible role played by the more 
hydrophobic PM 2 in the context of the microbial membrane, to which corresponded also a 
diminished cytotoxicity level with the respect to PM-C (Table 1). Indeed, among all the tested PMs, 
the compound 2 showed a very high hydrophobic component of the solvent accessible surface area 
(SASA) (saturated carbon and attached hydrogen) and the highest cLogPo/w, which was followed in 
the order by 1 > C > 5d > 5b > 5c > 5a (Table 2 and Table S2).  
 
Figure 2. Kill curves of Staphylococcus aureus 25923 (A) and Pseudomonas aeruginosa 10145 (B) 
planktonic cells after challenge with increasing concentrations of PMs for 24 h. 
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Among the nitro-PMs tested, the 5c, featuring NO2 and bromine substituents in R1 and R2 
positions respectively, was the most proficient in completely inhibiting S. aureus cell growth at a 
concentration as low as 1 μM, therefore being 90 times more active than PM-C. The nitro-PM 5b, yet 
prone in entirely inhibiting S. aureus growth, had higher MBCs (20 μM) as compared to the closely 
related 5c (Figure 2A, Table 1), where the main difference relied on the halogen element present in 
the R2 position of the pyrrolic nucleus, being either chlorine (5b) or bromine (5c). This result showed 
the importance of the halogen type in the position R2. Surprisingly, the new PM 5c showed a 
bactericidal activity of 1 μM against S. aureus. Since bromine has a lower electronegativity than 
chlorine, we surmise that the increased activity could be related to a change in the geometric 
conformation of pyrrolomycins induced by halogen replacement. These results are in contrast with a 
previous report [28] that demonstrated how the replacement of the chlorine by less electronegative 
halogens, e.g. bromine and iodine, resulted in a decreased antimicrobial activity. Importantly, the 
replacement of the chlorine with the bromine in 5c reduced also its cytotoxicity, as indicated by the 
selectivity index (SI; Table 1). Among the new nitro-PMs synthesized in this study, the nitro-PM 5c 
resulted to be 5-fold more active than the synthetic PM-1 that contains five bromines on its scaffold, 
being considered as the best synthetic pyrrolomycin obtained so far against S. aureus growth [5,9]. 
Besides, bacterial SI demonstrated how PM 5c is 30 times less toxic than PM-C (Table 1).  
Upon a change of the NO2 group position (R3 instead of R1) on the pyrrolic nucleus, as well as 
the presence of chlorine substituents in the R1 and R2 positions of the nitro-PM 5d, an increase of its 
MBC (7.5 μM) was observed. We hypothesize that its activity could be dependent on the synergistic 
effect derived from the protonophoric action combined with its high lipophilicity, as suggested by 
the gLogPo/w (Table 2).  
We evaluated whether the replacement of the two chlorine atoms of the PM-C pyrrolic ring with 
a single nitro group in R2 (5a) could affect the antibacterial activity of pyrrolomycins. Kill curve 
demonstrated that the nitro-PM 5a has maintained its ability to inhibit S. aureus with an MBC of 60 
μM, showing better bactericidal activity than PM-C. So far, our findings suggested the importance of 
the nitro group and its position in the pyrrolic nucleus for biological activity; besides, the lipophilicity 
also needs to be taken into account as a key factor influencing PM’s potency. We cannot rule out other 
mechanisms at the membrane or cell wall level. Indeed, in S. aureus sortase A was suggested as a 
specific target of PMs [9]. 
Table 1. Antibacterial activity and mammalian cell cytotoxicity of PMs (expressed in μM) analysed in 
this study. In bold the best-obtained values of minimal bactericidal concentration (MBC), IC50, and 
selectivity indexes versus cancer cells or bacteria. 
PMs 
MBCa 
P. aeruginosa 
MBCa 
S. aureus 
IC50 
HCT116 b 
IC50 
MCF 7 b 
IC50 
hTERT-RPE-1 b 
C-SI c B-SI d 
C >100 90 0.8 ± 0.3 1.5 ± 0.4 8.3 ± 1.9 10.4–5.5 >0.01–0.9 
1 >100 5 1.3 ± 0.3 1.2 ± 0.7 57.7 ± 11.2 44.2-47.3 >0.6–11.5 
2 >100 70 11.1 ± 3.3 17.2 ± 3.2 149 ± 41 13.4-8.6 >1.5–2.1 
5a >100 60 1.9 ± 0.42 2.2 ± 0.3 65.8 ± 10.5 34.6–29.2 >0.7-1.1 
5b >100 20 18.7 ± 3.8 28.8 ±4.2 55.4 ± 13.2 3–1.9 >0.6–2.8 
5c >100 1 7.6 ± 1.9 12.0± 2.8 29.7 ± 5.7 10.4–5.5 >0.3–29.7 
5d 30 7.5 1.6±0.2 1.6±0.4 224.9 ± 22.7 143.3–143.4 7.5–30 
a MBC: Minimum Bactericidal Concentration of PMs against P. aeruginosa and S. aureus. b IC50: 
Concentration of the PMs at which the proliferation of cancer HCT116, MCF 7 and the normal hTERT-
RPE-1 cells was inhibited by 50% with respect to the untreated growth control after 48 h of treatment. 
c CSI: Cancer Selectivity Index was defined as ratio of IC50 of normal hTERT-RPE-1 to that of HCT116 
and MCF 7 cancer cells, respectively. d BSI: Bacterial Selectivity Index was defined as ratio of IC50 of 
normal hTERT-RPE-1 to minimal bactericidal concentration (MBC) of P. aeruginosa and S. aureus, 
respectively. 
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The kill curve of P. aeruginosa highlighted how its growth can be completely inhibited by 5d, 
which featured an MBC of 30 μM, while the other PMs tested at the highest concentration (100 μM) 
determined, in the best-case scenario, either 2.7 (i.e., 5b) or 2.2 (i.e., 5c and 1) log reduction in the 
number of viable colonies forming units (CFUs), as opposed to PM-C, which did not display any 
antimicrobial effect (Figure 2B). Moreover, when P. aeruginosa cells challenged with a sub-inhibitory 
concentration of 5d (10 μM) were double-stained with both acridine orange (AO; membrane 
permeable) and ethidium bromide (EB; membrane impermeable) (AO/EB) (Figure 3), cells appeared 
either orange (indicating that cell membranes were damaged due to the entrance of EB) or red 
(indicating not viable cells), featuring, the latter, the presence of multiple division septa. Differently, 
cells treated with 100 μM of PM-C appeared green as well as the untreated cells. It is noteworthy to 
highlight that the main difference between PM-C and 5d relies only on the presence of the nitro group 
in the position R3 of the latter, which is likely responsible for its enhanced electronegativity and, 
therefore, better biological reactivity over PM-C. 
 
Figure 3. Fluorescence micrographs of P. aeruginosa cells treated for 24 h with 100 μM of PM-C or 10 
μM of PM 5d after AO/EB double staining. Control represents untreated cells. Green (AO) are viable 
cells, red (EB) dead cells, and orange vital cells with damaged membranes. 
To the best of our knowledge, 5d represents one of the best PMs holding a strong bactericidal 
activity against a Gram-negative bacterial strain reported so far. Indeed, the MIC of several natural 
PMs (C, G, H, I, J) was found to be more than 300 μM against Escherichia coli [11,29]. PMs resulted 
very active against Gram-negative bacteria only when the strains were impaired in the membrane 
permeability or in the efflux system [11,29,30]. Indeed, MIC values of PMs against E. coli strain were 
strongly reduced only in the case of the ∆imp strain, a mutant in the gene encoding for a protein 
responsible for the membrane permeability and necessary for cell envelope biogenesis, as well as in 
the case of the ∆tolC one, a mutant deleted in the gene involved in the biosynthesis of a tripartite 
efflux pump [29,30].  
Infections caused by Gram-negative bacteria are usually more difficult to eradicate than those 
caused by Gram-positive ones because of the presence of an additional outer membrane layer, which 
protects the cell from the entrance of foreign molecules [31–37]. Therefore, we assume that the 
presence of a more electron-withdrawing group on the pyrrolic ring increases the acidity of the 
hydrogen in N1 by an inductive effect, hypothesizing also that the introduction of the nitro group 
changes PM 5d’s lipophilicity, therefore facilitating its passage through the outer membrane. Thus, 
5d could represent a lead compound against infections caused by Gram-negative bacterial strains, 
with a very good selectivity index, which resulted to be higher than the highly cytotoxic and inactive 
PM-C (Table 1). 
2.3. Antitumoral and Cytotoxic Effects of new Pyrrolomycins 
In addition to the antibacterial activity, the anticancer effect of the PMs was investigated on colon 
(HCT116) and breast (MCF 7) cancer cell lines, by using the MTT assay (Figure 4A,B). The IC50 values, 
calculated from a dose–response model by fitting sigmoidal curves of the cell percentage inhibition 
versus the logarithmic concentration of treatments, are reported in Table 1. To evaluate the 
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cytotoxicity of PMs, the MTT assay was performed on the non-tumoral epithelial cell line (hTERT-
RPE-1) (Figure 4C and Table 1). Based on the percentage of viable cells after 48 h-challenge, the PMs 
could be divided in two groups, regardless of the cancer cell line investigated. Indeed, PM-C, 1, 5a, 
and 5d with IC50 values ranging from 0.8 ± 0.29 to 2.25 ± 0.35 μM resulted as more potent than the 
group containing PM 5b, 5c, and 2 with IC50 values higher than 7 μM (Figure 4A and B and Table 1). 
Interestingly, the recorded IC50 values are within the clinically acceptable concentration [38], 
suggesting a potential anticancer effect for all the new synthesized PMs. The structure–activity 
relationship was analysed by comparing the IC50 values of selected PMs. The compound 1 showed 
antitumoral activity comparable to that of the natural one PM-C, suggesting the importance of the 
halogen atoms (both chlorine and bromine) on the pyrrole and the phenyl rings for their biological 
activity. The effect of deprotonable groups (pyrrolic NH and the phenolic OH) in PMs induced-
cytotoxicity was confirmed comparing the IC50 values obtained for the compound 1 and the methoxy 
analogue compound 2. As expected, the PM 2 (IC50 values of 11.13 ± 3.26 μM (HCT116) and 17.25 ± 
3.2 μM (MCF 7)) was less active than PM 1 (IC50 values of 1.30 ± 0.35 μM (HCT116) and 1.22 ± 0.69 
μM (MCF 7)). Interestingly, once again compound 2 retained its biological activity also in the absence 
of deprotonable groups, suggesting that additional mechanisms besides the protonophoric action 
could be working in eukaryotic cells. Indeed, similarly to bacterial cells, the biological activity of PMs 
on eukaryotic cells could be dependent on the lipophilicity. The biological activity of PMs was 
modulated and improved by chemical changes on the pyrrolic ring. In particular, the introduction of 
a NO2 group in R3 (5d) or in R2 (5a) positions maintained the anti-proliferative effects against the 
cancer cell lines (being IC50 of 1.56 μM and 1.90 ± 0.425 for HCT116 and 1.57 ± 0.39 and 2.25 ± 0.35 for 
MCF 7). On the contrary, the introduction of a NO2 group in R1 position of 5b and 5c PMs reduced 
their antitumoral activity compared to PM-C. The analysis of the cLogPo/w showed a decreased 
hydrophobicity of both 5b and 5c PMs, even if both displayed a high electronegativity, lower only 
than 5d that resulted active. Similarly to bacteria, the replacement of the chlorine (5b) (IC50 of 18.68 ± 
3.81 and 28.75 ± 4.21 μM) with the bromine (5c) (IC50 of 7.64 ± 1.88 and 12.02 ± 2.85 μM) increased the 
biological activity of the latter. New findings were obtained by assessing the cancer selectivity index 
(C-SI) (Table 1). The C-SI was low for 5b, 5c, PM-C, and 2 (with mean values among the two cancer 
cell lines of 2.5, 8, 8, and 11), while higher C-SI values were found for compounds 1, 5a, and 5d (with 
mean values of 46, 32 and 143). Thus, the compounds 1, 5a, and 5d are less toxic than PM-C. Based 
on these results, PM 1, 5a, and 5d were selected for further investigations.  
The morphological evaluation of HCT116 cells treated with sub-inhibitory concentration (0.1 
μM) of compounds 1, 5a, and 5d in comparison to PM-C, was performed using a phase-contrast 
inverted microscope (Figure 5). The morphology of HCT116 consisted of a rounded and clumped 
morphology, while treated cells showed a more fibroblastic and less clumped morphology, became 
elongated with very long cell projection, resembling filopodia (thin membrane protrusions 
containing actin microfilaments cross-linked into bundles by actin-bundling proteins). These 
morphological changes in PMs-treated cells suggested that the impairment of biological membranes 
together with the cytoskeleton rearrangement could be due to PMs biological activity. In line with 
this evidence, several authors reported that PMs are able to bind plasma proteins and especially 
albumin [11,19], therefore, it cannot be excluded that PMs in eukaryotic cells could bind specific 
proteins. 
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Figure 4. Cytotoxic curves of HCT116 (A), MCF 7 (B) cancer cells and normal epithelial cell line 
hTERT-RPE-1 (C) after challenge with increasing concentrations of PMs for 48 h. 
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Figure 5. Inverted phase-contrast micrographs of HCT116 cells treated for 24 h with 0.1μM of selected 
PMs. Black arrows indicate cell projection, resembling filopodia Magnification 200×. 
Double staining with AO/EB of HCT116 cells treated for 24 and 48 h with the IC50 (Table 1) of 
the natural PM-C, the compound 1, 5a, and 5d was performed to verify whether the cell death was 
due to apoptotic induction or unspecific necrosis (Figure 6). As shown in Figure 6, untreated viable 
cells emitted green fluorescence due to the AO staining of both cytoplasm and nuclei. PM-C, 5a, and 
5d-treated cells exhibited orange fluorescence, indicating a possible induction of apoptosis upon 
treatment in a time dependent manner. Late apoptosis was evidenced by the presence of reddish 
orange cells, detected mainly in 5d treated cells after 48 h, supporting the less cytotoxicity and, 
therefore, pharmacological suitability of nitro-PMs as compared to the natural PM-C. Differently, PM 
1 treated cells emitted red fluorescence both at 24 h but with major extent at 48 h, suggesting that 
cytotoxic effect of the compound 1 is mainly due to necrotic cell death. Our results suggest the nitro-
PM 5a and especially the 5d could be used as new antitumor agents, for their potency, safety, and 
type of the induced cell death. 
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Figure 6. Fluorescence micrographs of HCT116 cells treated for 24 h and 48 h with PMs at IC50 after 
AO/EB double staining. Magnification 630×. Viable cells are uniformly stained in green, without 
nuclear alteration. Necrotic cells are intensely and uniformly stained in red, showing an increased 
cytoplasmic volume, while the apoptotic cells are green stained with bright orange or uniformly 
orange stained with condensed and/or fragmented nuclei. 
2.4. In silico ADMET (Absorption, Distribution, Metabolism, Elimination and Toxicity) Profile of New 
Pyrrolomycins 
Many promising molecules fail to enter in the clinical setting because to their poor 
pharmacokinetic profile. It is known that a potential drug should be safe and effective, easily 
administered, preferably orally, easily to absorb and capable of reaching the desired site of action. 
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Moreover, it should not produce toxic metabolites before exerting its pharmacological effect, 
eliminated easily to avoid the accumulation and consequently undesirable side effects.  
An effective in silico tool to predict the pharmacokinetic profile of drug candidates, in a short 
time and with lower costs than experimental approaches, is to consider their ADMET (absorption, 
distribution, metabolism, elimination and toxicity) properties. We used QikProp software (version 
6.2, Schrödinger, LLC, New York, NY, 2019) which allowed to compare the properties of each 
pyrrolomycin with those of 95% of the known drugs. The study permitted to predict 36 properties 
and the complete results are shown in the Table 2. All the calculated properties of the new 
synthesized pyrrolomycins, except for the weakly polar solvent accessible surface area (SASA) of 2, 
5b-d and the cLogP water/gas of 2, are included within the range of properties of 95% of known drugs 
indicating that pyrrolomycins 5a–d are promising drug candidates (Table S2). Furthermore, the 
pharmacokinetic profile of pyrrolomycins was implemented through the prediction of renal and 
hepatic clearance by pkCSM–pharmacokinetics web tool (Table S3) [39]. Overall, nitro-pyrrolomycins 
showed a better safety profile than 1 and C.  
In Table 2, we reported the most representative ADMET properties of the new pyrrolomycins 2, 
5a–d in comparison with PM-C and compound 1. Although the presence of the nitro group has 
changed the nitro-pyrrolomycins’ absorption, making them less absorbable orally and less capable of 
permeating intestinal and blood–brain barriers than PM-C and 1, overall there were no violations of 
Jorgensen's rule of three. Furthermore, their lower lipophilia than PM-C resulted in a lower ability to 
bind to plasma proteins, which was considered a pyrrolomycin toxicity factor. The absence of 
Lipinski’s violations indicated that nitro-pyrrolomycins are considered to be drug-like.  
Table 2. Calculated ADMET (Absorption, Distribution, Metabolism, Elimination and Toxicity) 
properties of PM-C, 1, 2, and 5a-d. 
heading PM-C 1 2 5a 5b 5c 5d 
Range 95% of 
Drugs 
cLogPo/w 4.476 4.889 5.637 2.496 3.200 3.132 3.746 −2.0/6.5 
cLogS −5.031 −6.250 −6.331 −4.126 −4.744 −4.945 −5.419 −6.5/0.5 
cLogKhsa 0.364 0.568 0.628 0.108 0.209 0.240 0.319 −1.5/1.5 
cLogBB 0.219 0.376 1.039 −1.138 −0.681 −0.890 −0.444 −3.0/1.2 
CNS Activity + + ++ − − +/− − +/− − − (inactive) 
++ (active) 
cLogHERG −4.511 −4.436 −4.259 −4.586 −4.583 −4.627 −4.515 concern below −5 
cPCaco 1298 1338 7162 131 277 175 344 
<25 poor 
>500 great 
clogKp −2.518 −2.594 −1.215 −4.245 −3.667 −4.111 −3.617 Kp in cm/hr 
Percent Human Oral 
Absorption ±20% 
100 100 100 79 89 85 94 <25% poor 
Jorgensen Rule 0 1 1 0 0 0 0 maximum 3 
Lipinski Rule 0 1 2 0 0 0 0 maximum 4 
# Stars (violation of the 
95% range) 
2 2 2 0 1 1 1 0-5 
cLogPo/w: predicted octanol/water partition coefficient. cLogS: predicted aqueous solubility, log S. S 
in mol dm-3 is the concentration of the solute in a saturated solution that is in equilibrium with the 
crystalline solid. cLogKhsa: prediction of binding to human serum albumin. cLogBB: predicted 
brain/blood partition coefficient. Note: Predictions are for orally delivered drugs. CNS Activity: 
predicted central nervous system activity on a−2 (inactive) to +2 (active) scale. cLogHERG: predicted 
IC50 value for blockage of HERG K+ channels. cPCaco: Predicted apparent Caco-2 cell permeability in 
nm/sec; Caco-2 cells are a model for the gut-blood barrier. Predictions are for non-active transport. 
cLogKp: predicted skin permeability, log K. Percent Human-Oral Absorption ±20%: predicted human 
oral absorption on 0 to 100% scale; the prediction is based on a quantitative multiple linear regression 
model; the assessment uses a knowledge-based set of rules, including number of metabolites, number 
of rotatable bonds, logP, solubility, and cell permeability. Jorgensen Rule or Rule of Three: number of 
violations of Jorgensen’s rule of three. The three rules are: cLogS > −5.7, cPCaco > 22 nm/s, # Primary 
Metabolites < 7. Compounds with fewer (and preferably no) violations of these rules are more likely 
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to be orally available. Lipinski Rule or Rule of Five: number of violations of Lipinski’s rule of five. 
The four rules are: mol_MW < 500, cLogPo/w < 5, HB donor ≤ 5, HB acceptor ≤ 10. Compounds that 
satisfy these rules are considered drug-like. # Stars (violation of the 95% range): number of property 
or descriptor values that are outside the 95% range of similar values for known drugs. A large number 
of stars suggests that a molecule is less drug-like than molecules with few stars. 
3. Conclusions 
In this study, we report on the synthesis of novel PMs showing a low cytotoxicity against normal 
epithelial cells and endowed with both antibacterial and antitumor activities against Gram-positive 
or -negative bacteria, as well as colon (HCT-116) and the breast (MCF 7) cancer cell lines.  
Our findings highlight that the biological activity of PMs is influenced by structural changes on 
the pyrrolic ring. Safe and active PMs were obtained by replacing chlorine with bromine or 
introducing nitro groups in different positions. Indeed, PM 5c could be considered as hit antibacterial 
compound in respect to S. aureus, and 5d against P. aeruginosa. Our results showed that the biological 
activity of PMs is due not only to the protonophoric action but also to the steric hindrance and 
narcotic effect derived from the lipophilicity of PMs in the context of cellular membranes. Moreover, 
non-orthodox cell morphology features were evidenced in both bacteria and cancer cells, after their 
treatment with PMs. It is well known that cytoskeleton is a dynamic network and a potential 
therapeutic target for new active molecules. Thus, the effect of PMs on cytoskeleton remodelling 
deserves further investigation.  
In conclusion, PMs are promising molecules not only for their biological activity, but more 
importantly for their mode of action on the membranes, because the emergence of drug (both 
antibiotic and antitumoral) resistance is hampered by the lack of a gene-encoded target.  
4. Experimental Section 
4.1. Chemistry 
4.1.1. Materials and instruments 
Melting points were determined on a Stuart Melting Point Apparatus SMP30 and are 
uncorrected. IR spectra were recorded at room temperature in KBr disks with a Perkin Elmer Infrared 
137 E spectrometer. 1H-NMR (300 MHz) and APT (75 MHz) spectra were recorded with a Bruker AC-
E spectrometer at room temperature in DMSO-d6, using tetramethylsilane as internal standard; 
chemical shifts (δ) are expressed as ppm values. Microanalyses (C, H, N) were carried out with an 
Elemental Vario EL III apparatus and agreed with theoretical values ± 0.4%. Automated flash 
chromatography was performed with a CombiFlash Rf200 system (TeleDyne ISCO) using Silica gel 
60 cartridges (0.040–0.063 mm, 230–400 mesh ASTM). All reactions were monitored by TLC on 
precoated aluminum sheets 20 × 20 (0.2 mm Kieselgel 60 G F254, Merck), using UV light at 254, 365 
nm for visualization. All reagents and solvents were from Aldrich, Merck, Across and Carlo Erba 
Reagents. ADMET properties were calculated by QikProp (version 6.2, Schrödinger, LLC, New York, 
NY, 2019) and pkCSM web tool. 
4.1.2. Methods 
Known compounds 1 and 3a–d were prepared and characterized as previously described [8,9].  
General procedure for nitration of (1H-pyrrol-2-yl)(3,5-dichloro-2-methoxyphenyl)methanones 
(3a–d) to obtain compounds 4a–d 
To a magnetically stirred solution of 3.13 mmoles of 3a–d in 20 mL of cold concentrated sulfuric 
acid (T = −10 °C), an equimolar amount of sulfonitric mixture was added. The reaction mixture was 
left under stirring for 15 minutes at −10°C, and crushed ice was then added. The (4-bromo-5-nitro-
1H-pyrrol-2-yl)(3,5-dichloro-2-methoxyphenyl)methanone 4c was isolated by filtration and 
crystalized from ethanol.  
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Compounds 4a,b,d were isolated by extraction with diethyl ether (3 × 50 mL). Then, the 
combined extracts were washed with brine (2 × 30 mL), dried over anhydrous sodium sulfate and 
evaporated. The crude products were purified by automated flash chromatography using a mixture 
of ethyl acetate/cyclohexane (v/v 20/80) as eluent, and then crystalized from ethanol.  
(3,5-Dichloro-2-methoxyphenyl)(4-nitro-1H-pyrrol-2-yl)methanone (4a) 
White solid, yield 65%, mp 162–164°C. 1H-NMR: δ 3.73 (s, 3H, OCH3), 7.16 (s, 1H, H-3), 7.57 (s, 
1H, H-6ꞌ), 7.86 (s, 1H, H-4ꞌ), 8.27 (s, 1H, H-5), 13.35 (br s, 1H, NH, exc. D2O). IR (cm−1): 3220 (NH), 1663 
(CO). Anal. calc. for C12H8Cl2N2O4: C, 45.74%; H, 2.56%; N, 8.89%. Found: C, 45.87%; H, 2.73%; N, 
8.98%. 
(4-Chloro-5-nitro-1H-pyrrol-2-yl)(3,5-dichloro-2-methoxyphenyl)methanone (4b) 
White solid, yield 56%, mp 158–160 °C. 1H-NMR: δ 3.73 (s, 3H, OCH3), 7.02 (s, 1H, H-3), 7.59 (s, 
1H, H-6ꞌ), 7.90 (s, 1H, H-4ꞌ), 13.25 (br s, 1H, NH, exc. D2O). IR (cm−1): 3230 (NH), 1671 (CO). Anal. calc. 
for C12H7Cl3N2O4: C, 41.23%; H, 2.02%; N, 8.01%. Found: C, 41.38%; H, 2.12%; N, 8.11%. 
(4-Bromo-5-nitro-1H-pyrrol-2-yl)(3,5-dichloro-2-methoxyphenyl)methanone (4c) 
White solid, yield 78%, mp 130–132 °C. 1H-NMR: δ 3.71 (s, 3H, OCH3), 7.03 (s, 1H, H-3), 7.55 (s, 
1H, H-6ꞌ), 7.88 (s, 1H, H-4ꞌ), 14.72 (br s, 1H, NH, exc. D2O). IR (cm−1): 3264 (NH), 1668 (CO). Anal. calc. 
for C12H7BrCl2N2O4: C, 36.58%; H, 1.79%; N, 7.11%. Found: C, 36.70%; H, 1.92%; N, 7.39%. 
(3,5-Dichloro-2-methoxyphenyl)(4,5-dichloro-3-nitro-1H-pyrrol-2-yl)methanone (4d) 
White solid, yield 45%, mp 168–170 °C. 1H-NMR: δ 3.71 (s, 3H, OCH3), 7.56 (s, 1H, H-6ꞌ), 7.85 (s, 
1H, H-4ꞌ), 13.84 (br s, 1H, NH, exc. D2O). IR (cm−1): 3174 (NH), 1618 (CO). Anal. calc. for C12H6Cl4N2O4: 
C, 37.54%; H, 1.58%; N, 7.30%. Found: C, 37.68%; H, 1.71%; N, 7.42%. 
General Procedure for Preparation of Pyrrolomycins 5a–d 
To a magnetically stirred solution of 1 mmol of 4a–d in 20 mL of anhydrous dichloromethane in 
an ice–salt bath, 30 mmoles of AlCl3 were added. The reaction mixture was left under stirring 
overnight at room temperature. The solution was cautiously decomposed with a cold 5% sulfuric 
acid solution (30 mL), then 50 mL of diethyl ether were added. The mixture was stirred vigorously 
for 10 minutes, the organic layer was separated and the aqueous phase extracted with diethyl ether 
(2 × 30 mL). The combined extracts were washed with brine until neutrality, dried over anhydrous 
sodium sulfate, and evaporated. The crude product was crystallized from dichloromethane to give 
pure pyrrolomycins 5a–d.  
(3,5-Dichloro-2-hydroxyphenyl)(4-nitro-1H-pyrrol-2-yl)methanone (5a) 
Yellow solid, yield 90%, mp 184–185 °C. 1H-NMR: δ 7.19 (s, 1H, H-3), 7.49 (s, 1H, H-6ꞌ), 7.76 (s, 
1H, H-4ꞌ), 8.27 (s, 1H, H-5), 10.51 (br s, 1H, OH, exc. D2O), 13.32 (br s, 1H, NH, exc. D2O). 13C-NMR: δ 
113.68, 123.44, 123.87, 126.56, 128.15, 130.68, 132.39, 137.36, 150.76, 183.27. IR (cm−1): 3583 (OH), 3206 
(NH), 1618 (CO). Anal. calc. for C11H6Cl2N2O4: C, 43.88%; H, 2.01%; N, 9.30%. Found: C, 43.97%; H, 
2.11%; N, 9.34%. 
(4-Chloro-5-nitro-1H-pyrrol-2-yl)(3,5-dichloro-2-hydroxyphenyl)methanone (5b) 
Yellow solid, yield 85%, mp 180–182 °C. 1H-NMR: δ 7.18 (s, 1H, H-3), 7.60 (s, 1H, H-6ꞌ), 7.87 (s, 
1H, H-4ꞌ), 11.23 (br s, 1H, OH, exc. D2O), 13.41 (br s, 1H, NH, exc. D2O). 13C-NMR: δ 109.13, 124.92, 
128.90, 129.19, 129.88, 132.97, 133.05, 141.98, 153.72, 166.39, 182.89.IR (cm−1): 3585 (OH), 3348 (NH), 
1629 (CO). Anal. calc. for C11H5Cl3N2O4: C, 39.38%; H, 1.50%; N, 8.35%. Found: C, 39.47%; H, 1.61%; 
N, 8.47%. 
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(4-Bromo-5-nitro-1H-pyrrol-2-yl)(3,5-dichloro-2-hydroxyphenyl)methanone (5c) 
Yellow solid, yield 52%, mp 175–177 °C. 1H-NMR: δ 7.03 (s, 1H, H-3), 7.56 (s, 1H, H-6ꞌ), 7.88 (s, 
1H, H-4ꞌ), 11.27 (br s, 1H, OH, exc. D2O), 14.60 (br s, 1H, NH, exc. D2O). 13C-NMR: δ 98.35, 121.01, 
123.10, 124.33, 127.67, 128.97, 133.06, 134.02, 138.57, 152.26, 183.47. IR (cm−1): 3534 (OH), 3298 (NH), 
1656 (CO). Anal. calc. for C11H5BrCl2N2O4: C, 34.77%; H, 1.33%; N, 7.37%. Found: C, 34.98%; H, 1.42%; 
N, 7.44%. 
(3,5-Dichloro-2-hydroxyphenyl)(4,5-dichloro-3-nitro-1H-pyrrol-2-yl)methanone (5d) 
Yellow solid, yield 85%, mp 180–182 °C. 1H-NMR: δ 7.51 (s, 1H, H-6ꞌ), 7.90 (s, 1H, H-4ꞌ), 10.21 (br 
s, 1H, OH, exc. D2O), 13.60 (br s, 1H, NH, exc. D2O). 13C-NMR: δ 105.15, 107.20, 111.26, 113.56, 130.03, 
130.69, 131.32, 137.15, 151.89, 180.94. IR (cm−1): 3568 (OH), 3317 (NH), 1641 (CO). Anal. calc. for 
C11H4Cl4N2O4: C, 35.71%; H, 1.09%; N, 7.57%. Found: C, 35.88%; H, 1.15%; N, 7.69%. 
Synthesis of the (3,5-Dibromo-2-methoxyphenyl)(3,4,5-tribromo-1-methyl-1H-pyrrol-2-
yl)methanone (2) 
To a magnetically stirred solution of 1 mmol of pyrrolomycin 1 in 10 mL of anhydrous 
dimethylformamide (DMF), 30 mmoles of K2CO3 were added and the suspension was stirred for 30 
minutes at room temperature to generate the salt. Then, 10 mmoles of CH3I were added under stirring 
at room temperature, and the reaction was monitored every 24 h on TLC. After 7 days, it was 
completed and the solvent was then removed under vacuum. Compound 2 was purified by 
automated flash chromatography using a mixture of ethyl acetate/acetone (v/v 50:50) as eluent and 
then crystalized from ethanol. 
(3,5-Dibromo-2-methoxyphenyl)(3,4,5-tribromo-1-methyl-1H-pyrrol-2-yl)methanone (2) 
White solid, yield 68%, mp 179–180 °C. 1H-NMR: δ 3.73 (s, 3H, NCH3), 3.92 (s, 3H, OCH3), 7.71 
(s, 1H, H-6ꞌ), 8.09 (s, 1H, H-4ꞌ). 13C-NMR: δ 37.86, 62.57, 104.48, 109.17, 116.80, 118.20, 118.65, 130.40, 
132.09, 136.30, 138.02, 154.31, 181.30. IR (cm−1): 1648 (CO). Anal. calc. for C13H8Br5NO2: C, 25.61%; H, 
1.32%; N, 2.30%. Found: C, 25.73%; H, 1.43%; N, 2.42%. 
4.1.3. In silico ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Calculation 
Pharmacokinetic studies to estimate the absorption, distribution, metabolism, excretion and 
toxicity (ADMET) of pyrrolomycins were performed by using QikProp Schrödinger (LLC, New York, 
NY, 2019). The molecular structures were designed in 3D and their conformations were optimized 
with the MMFF94 tool. Finally, the ADMET properties have been calculated with QikProp, running 
in normal mode, and by pkCSM—pharmacokinetics web tool [39]. 
4.2. Biology 
4.2.1. Biocidal and Inhibitory Activity of New Pyrrolomycins 
Kill curve assays were performed to test the antimicrobial efficacy of pyrrolomycins (i.e., 1, 2, 
5a, 5b, 5c, 5d), as well as that of the natural PM-C against the indicator pathogen Staphylococcus aureus 
ATCC 25923 and Pseudomonas aeruginosa ATCC 10145 strains. Briefly, a single colony of either S. 
aureus or P. aeruginosa strains was picked up and pre-cultivated (ca. 16 h) at 37 °C with shacking (160 
rpm) in Luria Bertani medium (hereinafter named as LB and composed of (g L−1): sodium chloride, 
10; yeast extract, 5; tryptone, 10). The same medium was solidified by adding 15 g L−1 of 
bacteriological agar when needed. Bacterial cells were then inoculated (1% v/v) in LB medium 
amended with increasing concentrations—ranging from 0 to 100 μM as initial concentration—of each 
pyrrolomycin tested, challenging the cultures for 24 h and incubating them as reported above. The 
actual number of viable colony forming units per milliliter of culture (CFU mL−1) of each bacterial 
strain, who survived the challenge exerted by pyrrolomycins, was evaluated through the spot plate 
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count method and compared to unchallenged cultures, as reported elsewhere [40–42]. The data are 
reported as average values (n = 3) of CFU mL−1 in the logarithmic (Log10) scale with standard deviation 
(SD). Evaluation of the MIC of PM-5c, and -5d against S. aureus and of PM-5d against P. aeruginosa 
was performed by incubating 1% (v/v) of an overnight bacterial suspension in LB medium in presence 
of increasing concentrations of the PMs. As a control, MIC of PM-C was measured. At the time of the 
inoculum and after overnight challenge, the absorbance of the cultures at 600 nm, which is an indirect 
way to measure the bacterial cell growth, was registered using a Spark™ 10 M multimode microplate 
reader measuring. The experiment was carried out in triplicate, being the absorbance corrected by 
subtracting that of the culture medium amended with the corresponding PM tested. 
4.2.2. Cell Cultures and Treatments 
The HCT116 colon cancer cell line (ATCC® CCL-247™), the MCF 7 breast cancer cell line (ATCC® 
HTB-22™) and the hTERT RPE-1 -immortalized retinal pigment epithelial cell line (ATCC® CRL-
4000™) used in this study were cultured in DMEM medium (Gibco, Paisley, UK), supplemented with 
1% glutamine, 10% heat-inactivated fetal bovine serum and 100U/mL penicillin and 100 μg/mL 
streptomycin, as already described [43–46], and maintained at 37 °C and 5% CO2.  
4.2.3. MTT Viability Assay 
Cells were plated at 5 × 103 cells/well in 96-well plates and incubated for 24 h prior to treatment 
for further 48 h of different concentrations of PMs. After incubation, a sample of 20 μL of Thiazolyl 
Blue Tetrazolium Bromide (5 mg mL−1) in PBS was added to each well and cultured for 2h at 37 °C in 
CO2 incubator. After removing the medium containing MTT and three washes with PBS, 100 μL of 
warm DMSO was added to each well to dissolve formazan. Samples were shaken for 10 min, at room 
temperature in the dark, and the absorbance was recorded at 570 nm using a microplate reader 
(Spark® 20M Tecan Trading AG, Switzerland). Percentage of cell viability with respect to untreated 
control cells (vehicle control) was calculated after subtraction of the blank. The IC50 values, that is the 
concentration necessary to inhibit the 50% of cell growth, was calculated using a dose-response 
model, obtained from sigmoidal fitting of response curves of percent inhibition versus logarithmic 
concentration of PMs, using Graph Pad Prism software. Each result represents the mean value of 
three different experiments performed in triplicate.  
4.2.4. Morphological Assessment and Acridine Orange/Ethidium Bromide (AO/EB) Staining 
HCT116 cells were seeded in 24 well culture plates with a cell density of 1 × 105 cells/well. After 
24 h cells were incubated for 24 h with different concentration of the selected PMs, and observed 
under a phase contrast inverted microscope (Carl Zeiss) at 200× magnification, for morphological 
changes assessment. 
For AO/EB, the cells were seeded at the same conditions in a cover slip and after 24h and 48 of 
IC50 treatments, cells were washed twice with PBS and stained for few minutes with 200 μL of the 
Acridine Orange (100 μg/mL), Ethidium Bromide (100 μg/mL) mixture (1:1, v/v). Cells were 
immediately observed under a fluorescent microscopy (Carl Zeiss) at 630 × magnification. 
Supplementary Materials: The following are available online at www.mdpi.com/2079-6382/9/6/292/s1, Figure 
S1: NMR spectra of new pyrrolomycins 2 and 5a–d. Table S1: MIC and MBC (expressed in μM) of PM-5c, -5d 
and -C. Table S2: ADMET properties of the pyrrolomycins C, 1, 2 and 5a–d calculated by QikProp software v6.2. 
Table S3: ADMET properties of the pyrrolomycins C, 1, 2 and 5a–d calculated by pkCSM–pharmacokinetics.  
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